Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 6

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 6
---
 6 months for ENGERIX - B vs. 81% for ENGERIX - B Launched : Feb. 2018 x 95%+ Protection after 1 month Record Annual Revenue in 2024 $268M Revenue CAGR 1 (2020 to 2024) ~65% 2020 → 2024 Market Share Growth 2 44% 26% HEPLISAV - B V accine Annual Net Product Revenue ($M) 6 | © Copyright DYNAVAX 2025 Source: Dynavax internal data , FactSet 1 Reflects CAGR for net HEPLISAV - B product sales from FY 2020 to FY 2024. 2 Market share data are for Q4 of each year and do not reflect interim periods. … Transforming into a Powerful Commercial - Stage Vaccine Company with More Room to Grow 36 62 126 213 268 0 50 100 150 200 250 300 2020 2021 2022 2023 2024 Achieved record annual HEPLISAV - B revenue in 2024 of $268M

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx © Copyright DYNAVAX 2025 We Didn’t Merely Survive Through the Pandemic – We Thrived Our Operations Have Delivered Significant and Positive Cash Flow Our Proprietary Adjuvant 1 (CpG 1018) Allowed Us To: 1 Drive Successful Business Development Strategy Dynavax generated >$950M in net product revenue from 2020 - 2022 (related to COVID - 19) from our CpG 1018 adjuvant, generating significant cash ($165M at YE 2020 vs. $624M at YE 2022) Launch and Grow HEPLISAV - B into the U.S. market - leading hepatitis B vaccine 2 (Plague Vaccine) 7 | $ 165 $ 546 $ 624 $ 742 $ 714 $0 $150 $300 $450 $600 $750 $900 2020 2021 2022 2023 2024 Cash and Equivalents ($M) 1 An adjuvant is a pharmac